Drug Discovery through Joint Research with Universities and Research Institutions and Expansion of Contract Research
First written in FY2021. 10 of 12 entries say "Advanced", first in FY2023. Latest entry: 2026-09-08.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「National University Corporation the University of Tokyo Joint Research Agreement 24 March 2026 31 March 2028 Joint research agreement concerning the design and evaluation of antibody molecules involved in disease and drug delivery」
The Company entered into a joint research agreement with the University of Tokyo concerning the design and evaluation of antibody molecules on 24 March 2026, with the agreement running through 31 March 2028. The Company also disclosed the continuation and extension of research agreements with Institute of Science Tokyo, Kagoshima University, Chubu University and others, further developing its research network. - FY2025AdvancedAnnual report
「National University Corporation Tokai National Higher Education and Research System (formerly National University Corporation Nagoya University) Joint Research Agreement 3 October 2018 (original agreement) 13 March 2025 Amendment Agreement (extension of term) 31 March 2026 Joint research agreement concerning research into treatments for blood cancers」
In addition to extending the research agreement on blood cancer treatments with the Tokai National Higher Education and Research System to 31 March 2026, the Company has expanded and continued its research network through amendments to agreements with Gunma University, Chubu University, the University of Tokyo and others, and a joint research agreement with Kagoshima University. - FY2024AdvancedAnnual report
「National University Corporation Gunma University Japan Joint Research Agreement 19 April 2019 (original agreement) 1 March 2024 Amendment Agreement (extension of term) 31 March 2026 Joint research agreement concerning therapeutic efficacy using antibodies」
In addition to extending the joint research agreement with Gunma University to 31 March 2026, the Company extended or amended its joint research agreements with the Tokai National Higher Education and Research System, the University of Tokyo, Tokai University, Osaka University and others, continuing to develop its joint research network. - FY2024-Q3AdvancedAnnual report
「National University Corporation Gunma University Japan Joint Research Agreement 19 April 2019 (original agreement) 17 October 2023 Amendment Agreement (extension of term) 31 March 2024 Joint research agreement concerning therapeutic efficacy using antibodies」
The term of the joint research agreement with Gunma University concerning therapeutic efficacy using antibodies was extended to 31 March 2024 under an amendment agreement dated 17 October 2023. - FY2023AdvancedAnnual report
「Tokai University Educational Corporation Joint Research Agreement 27 March 2023 Joint research agreement concerning treatments for lymphoid and myeloid malignancies, centered on aggressive NK-cell leukemia, using anti-transferrin receptor antibodies and other agents」
The Company entered into a joint research agreement with Tokai University concerning ANKL and related conditions on 27 March 2023, giving concrete form to its joint research network with universities and research institutions. - FY2021First statedAnnual report
「For new research themes, the Company is actively conducting joint research with universities and research institutions nationwide. In addition, through technical discussions in the course of joint research, the Company will promote orders for antibody research support services.」
Indicates a policy of using joint research with universities not only to create new research themes but also to generate orders for antibody research support services.